Cubist’s Feverish Weekend: Rapid Response To Friday’s Cubicin “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says its March 27 response to FDA clears up labeling issues related to infective endocarditis indication for daptomycin.
You may also be interested in...
Cubicin Indication Expands To Cover S. Aureus Bacteremia
Cubist says daptomycin injection is the only IV antibiotic approved for S. aureus bloodstream infections.
Cubicin Indication Expands To Cover S. Aureus Bacteremia
Cubist says daptomycin injection is the only IV antibiotic approved for S. aureus bloodstream infections.
Panel Split On Whether Cubicin Should Be Approved For Infective Endocarditis
FDA's Anti-Infective Advisory Committee recommends use of daptomycin in S. aureus bacteremia patients.